![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » AFFYMAX AND TAKEDA ANNOUNCE COMPREHENSIVE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF HEMATIDE FOR ANEMIA
AFFYMAX AND TAKEDA ANNOUNCE COMPREHENSIVE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF HEMATIDE FOR ANEMIA
June 27, 2006
Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced that the companies have entered into an exclusive global agreement to develop and commercialize Affymax's lead product candidate, Hematide, for the treatment of anemia.
Drug Newswire (http://www.drugnewswire.com/2679/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct